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OBJECTIVES: Evaluate adherence to the therapeutic prophylaxis protocol for venous thromboembolism (VTE) as
well as the costs of this practice.
METHODS: A descriptive and cross-sectional study was conducted at a State General Hospital in Brazil through
reports of drug dispensions, prescriptions and risk stratification of patients. Adherence to the VTE prophylaxis
protocol was monitored. The tests for VTE diagnosis measured the adherence to therapeutic prophylaxis
treatment, and the purchase prices of the drugs went into the calculation of drug therapy costs. The level of
adherence to prescriptions for VTE prophylaxis in the hospital was classified as ‘‘adherence’’, ‘‘non-adherence’’
and ‘‘justified non-adherence’’ when compared with the protocol.
RESULTS: Protocol adherence was observed for 50 (30.9%) patients, and non-adherence was observed for
63 (38.9%) patients, generating an additional cost of $180.40/month. Justified non-adherence in 49 (30.2%)
patients generated $514.71/month in savings due to a reduction in the number of daily administrations of
unfractionated heparin while still providing an effective method for preventing VTE. Twenty-six patients
stratified as having medium to high risk of VTE who did not receive prophylaxis were identified, generating
$154.41 in savings. However, these data should be evaluated with caution since the risks and outcomes
associated with not preventing VTE outweigh the economy achieved from not prescribing a drug when a
patient needs it. The only case of VTE identified during the study period was related to justified non-adherence
to the protocol.
CONCLUSION: The protocol is based on scientific evidence that describes an effective therapy to prevent VTE.
However, the protocol should be updated because the justifications for non-adherence are based on scientific
evidence, and this justified non-adherence generates savings and yields effective disease prevention.
KEYWORDS: Venous Thromboembolism; Pharmaceutical Economics; Quality Indicators; Patient Safety; Safety
Management.
’ INTRODUCTION
The term venous thromboembolism (VTE) is used to denote
the combination of two pathologies: deep venous thrombosis
(DVT) and pulmonary thromboembolism (PTE), which is the
more serious clinical condition (1). During the hospitalization
period, half of patients are at risk of developing VTE, and the
incidence is higher among surgical patients (2,3).
Despite the high incidence (approximately 104 to 183/
100,000/year) and severity of VTE, it is a preventable cause
of morbidity and mortality in hospitalized patients (4) and
is highly preventable when adequate prophylactic measures
are performed (5). Therefore, the application of evidence-
based prophylactic measures in surgical patients in the
hospital setting may reduce the number of individuals
affected by VTE and its consequences (6). However, even
with well-established guidelines, VTE prophylaxis is not
always properly practiced (3,7).
Unfractionated heparin (UFH) and low-molecular weight
heparin (LMWH) are among the drugs used in the prophylaxis
protocol, and both correspond to approximately 6% of the
monthly cost of purchasing drugs in the hospital setting (8).
In this context, quality management tools that monitor
adherence to established protocols are relevant in promoting
the rational use of prophylactic therapy, aimed at reducing
the incidence of DVT and PTE at the lowest cost and with
methods based on scientific evidence.
Thus, we aimed to evaluate adherence to the criteria of the
care protocol for prophylactic VTE therapy and the costs
generated by this practice in a single hospital.DOI: 10.6061/clinics/2019/e1143
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’ METHODS
Study design and setting
This is a descriptive and cross-sectional study carried out
at Américo Brasiliense State Hospital (HEAB), a medium-
sized general hospital linked to the Public Health System
(SUS) of Brazil.
The project was approved by the Scientific Project Analysis
Committee of the hospital.
Patients
The VTE care protocol determines measures of and thera-
peutic prophylaxis for moderate risk and high risk of VTE.
For moderate risk, subcutaneous UFH 5,000 IU / 0.25 mL
twice daily or a subcutaneous LMWH-filled syringe 20 mg /
0.2 mL once per day is recommended; for high risk, a
subcutaneous UFH ampoule 5,000 IU / 0.25 mL three times a
day or LMWH 40 mg / 0.4 mL once daily is recommended
(8). Mechanical prophylaxis is indicated when inpatients are
unable to use UFH or LMWH due to renal impairment,
overcoagulation, or old age, among other conditions.
The prophylactic drug therapy for VTE should be adminis-
tered only to patients stratified as moderate- and high-risk
and according to some criteria established in the protocol
(Table 1).
Participants were recruited if they experienced two triggers:
1) hospital prescription of UFH 5000 IU and/or LMWH 20 mg
or 40 mg; and 2) inpatient status as well as submission to
imaging exams (tomography, angiotomography of the thorax
and Doppler ultrasonography of limbs). Therefore, inpatients
met the inclusion criteria when they received prescriptions
of UFH 5000 IU and/or LMWH 20 mg or 40 mg for VTE
prophylaxis or the diagnosis of VTE (Figure 1).
The medical records of patients prescribed UFH 5000 IU
or a full-dose of LMWH (1 mg/kg) associated with oral
anticoagulants were excluded from this study. This associa-
tion is used for the treatment of PTE and has resulted in a
reduction in hospital stay (10). However, for inpatients with
a diagnosis of VTE confirmed by imaging exams, we perfor-
med a review of records to assess whether these patients
received prophylaxis according to our institutional protocol.
Chart review was carried out for enrolled inpatients to
assess the adherence to prescription of VTE prophylaxis
according to the risk stratification described in the institu-
tional protocol and the costs associated with adherence and
non-adherence to the drug therapy protocol.
Risk stratification was performed at HEAB by an algo-
rithm based on the Rogers score (9). The algorithm assigns a
score to each risk factor, and the sum of the assigned points
stratifies the patient into low, medium- or high-risk cate-
gories. The risk factors investigated included advanced age,
DVT or PTE for more than two years, obesity, prolonged
surgery with 60 minutes under anesthesia, and paralysis of a
lower limb, among others (9).
The Rogers score is often used as a standard because of its
simplicity of application and reproducibility, since the
laboratory tests, such as sodium and albumin levels, required
for the Rogers score are usually collected as part of routine
patient hospitalization. This score is also used by the Clinical
Hospital of the Medical School of the University of São Paulo
(USP), and although the American College of Chest Physi-
cians (ACCP) supports the use of the Caprini score, this score
requires more complex exams that may make it difficult to
execute and deploy.
Data and measures
Data were collected three months after protocol imple-
mentation. Data collection was performed through the
hospital pharmacy dispensing report and was complemen-
ted with the information on the dossier of the received
prophylactic therapy (UFH 5000 IU and/or LMWH 20 mg or
40 mg) in addition to the clinical conditions of the patient,
including the Rogers score risk stratification analysis.
To perform chart review and identify and collect the data
of patients stratified into the medium- and high-risk cate-
gories and who did not receive prophylactic therapy, the
Athos - Hospital Assistance System of HEAB was consulted.
Athos is a consolidated electronic medical records system
with the information and anamnesis of a multiprofessional
team in addition to the results of clinical and laboratory tests.
The results of tomography and angiotomography of the
thorax and Doppler ultrasonography of limbs were con-
sulted during the patients’ hospitalization to collect the cases
of VTE and to evaluate whether the patient received the drug
therapy described in the protocol.
The descriptive variables studied were the level of
adherence to the protocol criteria ("adherence", "non-adher-
ence" or "justified non-adherence"), the prescribers, the ward
where patients were hospitalized and received or should
have received drug therapy, and the cost of therapy accor-
ding to the type of adherence to the protocol, and an econo-
mic evaluation was performed.
"Adherence" was considered the fulfillment of all the
criteria established in the VTE care protocol; "non-adher-
ence" was non-adherence to at least one criterion established
in the protocol without any justification; and "justified non-
adherence" was non-adherence to the protocol but with
justification based on scientific evidence. A patient hospita-
lized for several days who had more than one prescription
was stratified into the category "adherence" when all the
prescriptions complied with the protocol. Failure to comply
with the protocol on any patient prescription prompted
placement in the "non-adherence" group. Finally, when the
patient received at least one prescription that did not comply
Table 1 - Criteria for indication of the therapeutic prophylaxis
for VTE according to the clinical conditions of the patient and
the care protocol.
Clinical condition Indication of therapeutic
prophylaxis according to protocol
Creatinine clearance
o30 mL/minute
Preferably use UFHa 5000 IU
subcutaneously 12/12 h. If you use
LMWH, use a 20 mg subcutaneous
dose once daily
Morbid obesity (BMI440) Use UFH 7,500 IU 8/8 h
Full anticoagulation, heparin
hypersensitivity, heparin-
induced thrombocytopenia
and active bleeding
Absolute contraindication for the
use of prophylactic therapy
Recent intracranial or ocular
surgery, CSF collection in the
last 24 h, uncontrolled
arterial hypertension
(4180x110 mmHg)
Relative contraindication for the
use of prophylactic therapy
Stroke Preference for the use of LMWH
aUFH: unfractionated heparin; LMWH: low-molecular-weight heparin;
BMI: body mass index; CSF: cerebrospinal fluid.
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with the protocol, with justification, and none without
justification, this was considered "justified non-adherence ".
The dichotomous variable studied was the presence or
absence of DVT/PTE, according to patient adherence to the
protocol criteria.
Economic analysis
The currency used for the costs in the present study was
the dollar. For the economic evaluation of each type of
adherence, a "referential adherence" was established, that is,
the theoretical cost if the protocol had been followed in full.
The cost of "referential adherence"was calculated using the
following formula:
Cra¼Vestimated x Iestimated xNnc
Cra: cost of referential adherence.
Vestimated: unit value of the drug to be used according to
the protocol (UFH 5,000 IU or LMWH 20 mg or 40 mg).
Iestimated: dosing interval that should be used according to
protocol (two or three times daily).
Nnc: absolute frequency of hospitalization.
The same formula and reasoning were adopted for the
calculation of the cost of non-adherence (Cna) and the cost of
justified non-adherence (Cnaj).
To evaluate the difference between the cost of adherence
and the cost of non-adherence to the protocol (with or
without justification), the following formula was used:
E¼Cra2Cna
In the case of justified non-adherence, the formula was:
E¼Cra2Cnaj
E: economic evaluation.
Figure 1 - Recruitment, chart review, evaluation of protocol adherence and economic analysis of patients with venous
thromboembolism.
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Cra: cost of referential adherence.
Cna: cost of non-adherence.
Cnaj: cost of justified non-adherence.
Statistical analysis
The collected data were tabulated in a spreadsheet using
Microsoft Excels 2013. Data were analyzed through descrip-
tive statistics to present the simple and relative frequencies of
the variables.
’ RESULTS
A total of 162 patients eligible for the study were identified.
We analyzed 1208 prescriptions, of which 123 included
therapeutic prophylaxis for VTE. In addition, 39 prescriptions
were associated with patients stratified as having medium or
high risk and who did not receive prophylaxis.
The most frequent diagnoses of patients who received VTE
prophylaxis in the study period were bacterial and viral
pneumonia, chronic obstructive pulmonary disease, stroke,
congestive heart failure and malignant neoplasms.
Adherence to the VTE protocol was identified in 50 patients
(30.9%) (Table 2). Non-adherence to one or more protocol
criteria was identified in 63 patients (38.9%), of whom 26 were
stratified as having medium or high risk and did not receive
prophylaxis without any contraindications. Justified non-
adherence was observed for 49 patients (30.2%) [UFH twice
daily for high-risk patients] (Table 3).
Regarding the prescriptions analyzed [1208], adherence to
the protocol was observed in 457 prescriptions (37.8%)
(Table 2). In 231 (19.1%), there was non-adherence to the
protocol without justification. Non-adherence was justified
for 520 prescriptions (43%) (Table 3).
The justified non-adherence generated a savings of
$514.12/month; however, non-adherence without justifica-
tion generated an additional cost of $180.20 in the analyzed
month (Table 3).
No differences were observed in the frequency of non-
adherence to the protocol for prophylactic VTE therapy
according to the ward or prescriber. In addition, there was
uniformity in practice among the 65 physicians responsible
for the prescriptions analyzed.
Table 2 - Description, frequency and cost of adherence to the criteria of the prophylaxis therapy protocol for venous
thromboembolism (VTE).
Description of protocol criteria Patient (N)a Prescription (N) (N)b Cost of adherence ($)c
UFHd 8/8 h for patient at high risk 49 343 1014.93
UFH 12/12 h for patient with clearance o30 mL/minutes 16 183 361.02
Nonreceipt of prophylaxis for patient with contraindication 13 25 0
UFH 12/12 h for average patient risk 01 13 25.65
LMWH 40 mg for high-risk patients with justification 03 06 20.58
UFH for low-risk patients with justification 0 0 0
UFH 7,500 IU 8/8 h for morbidly obese patients 0 0 0
LMWH 40 mg with justification (low-risk patients) 0 0 0
LMWH 40 mg with justification (medium-risk patients) 0 0 0
Total 50 457 1422.18
a Total number of patients.
b The total number of prescriptions is less than the sum of all items because the same patient and/or same prescription has been evaluated for more than
one criterion.
c Value of the dollar: 1 dollar = 3.92 Brazilian Reais.
dUFH: unfractionated heparin; LMWH: low-molecular-weight heparin.
Table 3 - Description, frequency, cost of non-adherence (with and without justification) and of referential adherence, and economic
analysis, according to the criteria established in the prophylaxis protocol for venous thromboembolism (VTE).
Patient
(N)a
Prescription
(N)
Cost of non-
adherence ($)b
Cost of referential
adherence ($)
Economic
analysis ($)
Description of justified non-adherence
UFHc 12/12 h for patients at high riskd 54 520 1027.37 1541.06 513.69
Description of non-justified non-adherence
UFH for patients at risk without justification 19 167 390.20 0 -390.20
LMWH 40 mg for high-risk patients without justification 13 31 109.95 91.87 -18.07
LMWH 40 mg and UFH 5000 IU for morbidly obese patients 04 33 101.71 195.60 93.89
LMWH 40 mg for low-risk patients without justification 02 07 24.05 0 -24.05
LMWH 40 mg for medium-risk patients without justification 02 02 6.87 3.95 -2.92
UFH 8/8 h for patients with clearance o30 mL / minutes 01 11 32.60 21.73 -10.87
Nonreceipt of prophylaxis without contraindications 26 59 0 154.11 154.11
UFH 8/8 h for medium-risk patients 0 0 N/A N/A N/A
Subtotal 63 231 665.38 467.26 -180.05
Total 112 751 1692.75 2008.31 333.64
a The total number of patients and prescriptions is less than the sum of all items because the same patient and/or the same prescription were evaluated for
more than one criterion.
bValue of the dollar: 1 dollar = 3.92 Brazilian reais.
c UFH: unfractionated heparin; LMWH: low-molecular-weight heparin; N/A: not applicable.
dGeerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism: American College of Chest
Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133.
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From another perspective, there was only one record of
VTE. A female patient, 63 years old, with moderate obesity,
hypertension and dyslipidemia, was hospitalized at HEAB for
neurological rehabilitation of hemorrhagic stroke. Throughout
the entire hospitalization the patient received VTE prophy-
laxis, and in the first two days of hospitalization, the protocol
was not fulfilled with justification. Subsequently, until hospital
discharge, the protocol was fulfilled. However, on the 10th
day, the patient evolved with respiratory arrest, was trans-
ferred to the intensive care unit with suspected acute myocar-
dial infarction and was later diagnosed with PE.
Due to the recent hemorrhagic stroke, full anticoagulation
was not performed. A vena cava filter was implanted in the
patient, which effectively prevented mortality. After dis-
charge (28 days of hospitalization), the patient was referred
to a qualified hospital to begin full anticoagulation therapy.
’ DISCUSSION
The incidence of PTE increased from 23/100.000/year in
1993 to 65/100.000 in 2012 (12).
Studies with hospitalized patients have demonstrated that
the incidence of VTE cases can vary between 0.52 and 0.97%
(13,14). In the present study, only one case of VTE (PTE) was
recorded (0.6%), similar to another study that identified only
one case during the one-year experience reported after the
implementation of the VTE prophylaxis protocol (15). The
case also occurred with an obese female patient, 57 years old,
after her hospital discharge (15). This low incidence may
corroborate the hypothesis that VTE therapeutic prophylaxis
is effective. Regarding the case of VTE, it was observed that
the justified non-adherence to the prophylaxis protocol could
not be considered the sole cause of the PTE. The patient, who
received VTE prophylaxis for two days with reduction in
the daily dose of UFH, already had some risk factors for the
development of VTE. Hemorrhagic stroke, obesity and old
age are important risk factors (16,17). In addition, hemor-
rhagic stroke may increase the risk of VTE by five times (18),
and age over 40 years significantly increases the risk of VTE,
which doubles every subsequent decade (16).
Furthermore, the causality between therapeutic ineffec-
tiveness and justified non-adherence to the protocol was
considered improbable despite a reasonable temporal rela-
tionship between the prophylaxis administration and the
diagnosis of PTE, since the thrombotic event could be
explained by other clinical factors (19).
As described in Table 2, the criterion "prescription of UFH
7,500 IU for morbidly obese patients" was not fulfilled for any
patient. This was probably due to the absence of the 7,500 IU-
compatible dosage in the Brazilian market, and dosage using
two UFH 5,000 IU ampoules would generate waste.
The most recent Clinical Practice Guidelines of the ACCP
recommend, in addition to HFN 7,500 IU three times daily,
prophylactic treatment with LMWH 40 mg twice daily for
these patients (20). Thus, it is recommended that the dosage
for these patients be updated in the protocol so that they
do not receive UFH subdoses and that there is no waste of
the drug.
For moderately obese patients (body mass index o40),
such as patients diagnosed with PTE, the ideal dosage of
prophylactic therapy is not clearly defined due to the poor
quality of evidence (20).
Another criterion of the protocol that was not followed,
with justification, was the prescription of prophylaxis for
patients with low risk. According to the ACCP guidelines,
patients stratified as low risk should not receive therapeutic
prophylaxis but should receive only mechanical prophylaxis
(21). Therefore, it is considered important that the prescrib-
ing physician justify this practice in patient medical records
when the application of prophylactic therapy to low-risk
patients is deemed necessary.
Despite the lack of clear evidence in the literature regard-
ing which drug is most cost-effective (UFH or LMWH), the
choice between the two drugs may be related to local factors
that affect acquisition costs (21). Because the acquisition
of UFH is less expensive, the HEAB care protocol mostly
recommends the use of UFH. However, other factors may
interfere with this decision, such as the preference of the
prescriber and the ease of administration in the patient (21).
Therefore, it is suggested that the factors described in the
protocol should be considered by the prescriber to avoid
unnecessary hospital expenses.
Similarly, according to the ACCP guidelines, there is no
robust evidence to show that administration of UFH three
times a day confers a greater risk of bleeding or greater
effectiveness in relation to administration of UFH twice daily
(21). The low incidence of VTE demonstrated in this study
strengthens this premise, since a significant proportion of the
patients analyzed (30.2%) received prophylaxis with UFH
twice daily. In addition, for the only case of VTE detected, the
patient had other risk criteria that could explain the event.
The similarity between the numbers of patients who
received the two types of prescriptions [three times a day (49)
and twice a day (54)] suggests that prescribers were aware of
recent evidence that shows no risk of bleeding with the use
of UFH three times a day and no lowered effectiveness with
the use of UFH twice daily. Furthermore, twice daily UFH
administration, which generates a savings of $514.71/month,
is more commonly acceptable and better tolerated by the
patient than three daily injections (21). Therefore, the twice
daily dosage is considered the best option because it corro-
borates with the rational use of drugs (use of drugs appro-
priate for clinical conditions, in doses appropriate to the
individual needs, for an appropriate period and at the lowest
cost) (22) and because there are no differences in safety or
effectiveness. For this reason, we suggest updating the
relevant healthcare protocol of HEAB based on scientific
evidence, a task assigned to the Hospital’s Pharmacy and
Therapy Commission (23).
Although adherence to the protocol was only 30%, this
was calculated before an educational intervention to promote
behavioral changes and improve adherence to the protocol
and before the update of the protocol to the highest evi-
dentiary standard, according to the data obtained from
protocol monitoring.
The monitoring of protocol adherence is an indicator of
hospital healthcare assistance and consists of a quality tool
and comprehensive management. Furthermore, despite the
development of prevention and treatment strategies, VTE
remains a burden on public health (24).
In this sense, the importance of the clinical pharmacy in
the management of clinical protocols is emphasized because
the professionals in this area have specialized therapeutic
knowledge, being able to assist in the choice of adequate
therapy and the duration of the therapy and to discuss the
cost effectiveness of treatment options (25–27).
Thus, monitoring adherence to protocols has two benefits:
one that contributes to patient safety, fostering the practice of
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prophylactic therapy that is based on scientific evidence and
best suited to the clinical conditions of the patient; and one
that aims at reducing costs for the institution since clinical
protocols recommend the most cost-effective treatments (28).
The recruitment technique of this study was unable to
identify patients at risk of VTE and who were not using
prophylactic therapy because the medical records analysis
was based on the recruitment of patients with LMWH or
UFH prescriptions and with a diagnosis of VTE. We were
unable to assess the use of mechanical devices because the
hospital did not use electronic registration with the dispen-
sing of these items. Thus, we were unable to identify patients
who received a prescription for such devices. In addition,
the short collection period may be an important limitation
of this study because it did not allow the identification of
seasonality, but it was possible to analyze all admissions in
the study period.
Another limitation was that the economic analysis
considered only the costs of drug therapy, disregarding
other expenses arising from the patient’s hospitalization and
related complications.
’ CONCLUSION
The prophylaxis protocol considered in this study is based
on scientific evidence that describes drug therapies that
are effective for VTE prevention. The highest cost of non-
adherence to the protocol came from administration in low-
risk-stratified patients who, according to the protocol, should
not receive therapeutic prophylaxis. The prescription of
prophylaxis in these cases is considered unnecessary and
contributes to extra costs to the hospital.
The savings generated by non-adherence refers to non-
administration of the drug to medium- and high-risk patients
and/or the administration of underdoses to obese patients
due to the lack of availability of the specialty dosage
(7,500 IU). However, despite the savings generated, patients
without prophylaxis have a higher risk of developing VTE.
Thus, the costs associated with prophylaxis therapy should
not outweigh the benefits associated with preventing
negative outcomes in inpatients.
An alternative to reduce the costs associated with the
prevention of VTE in the hospital is to update the protocol.
Justified non-adherence generated savings due to the
omission of one administration/day of UFH for patients at
high risk, which is still effective for prophylaxis. Therefore,
the Pharmacy and Therapeutic Commission could standar-
dize the dose of heparin to twice a day instead of the three
times described in the protocol.
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